The University of Southampton
University of Southampton Institutional Repository

Cost-effectiveness of implantable cardioverter defibrillator therapy

Cost-effectiveness of implantable cardioverter defibrillator therapy
Cost-effectiveness of implantable cardioverter defibrillator therapy
Cost-efficacy assessment of implantable cardioverter defibrillator (ICD) therapy has proved contentious and may have limited uptake of ICD therapy, particularly in Europe. Published modeling assessments are too inaccurate to determine clinical practice, and assessments based on clinical studies are incomplete (from the cost-efficacy viewpoint). Although ICD therapy seems certain to be most cost-effective in patients who are likely to have good longevity if their risk of sudden cardiac death is countered, the benefit of ICD therapy is not necessarily limited to such groups. Physicians and health economists need to develop a better understanding of how to assess high-technology therapy costs so that uptake of such therapy is appropriately expedited with due regard to ethical and cost constraints.
1045-3873
S114-S117
Morgan, J.M.
e1a187e2-3fae-414d-86b6-dfe336ec94f9
Morgan, J.M.
e1a187e2-3fae-414d-86b6-dfe336ec94f9

Morgan, J.M. (2002) Cost-effectiveness of implantable cardioverter defibrillator therapy. Journal of Cardiovascular Electrophysiology, 13 (1 Suppl), S114-S117.

Record type: Article

Abstract

Cost-efficacy assessment of implantable cardioverter defibrillator (ICD) therapy has proved contentious and may have limited uptake of ICD therapy, particularly in Europe. Published modeling assessments are too inaccurate to determine clinical practice, and assessments based on clinical studies are incomplete (from the cost-efficacy viewpoint). Although ICD therapy seems certain to be most cost-effective in patients who are likely to have good longevity if their risk of sudden cardiac death is countered, the benefit of ICD therapy is not necessarily limited to such groups. Physicians and health economists need to develop a better understanding of how to assess high-technology therapy costs so that uptake of such therapy is appropriately expedited with due regard to ethical and cost constraints.

This record has no associated files available for download.

More information

Published date: 2002

Identifiers

Local EPrints ID: 25823
URI: http://eprints.soton.ac.uk/id/eprint/25823
ISSN: 1045-3873
PURE UUID: 4510805f-9d46-4d0a-9c08-22142210433a

Catalogue record

Date deposited: 11 Apr 2006
Last modified: 08 Jan 2022 15:52

Export record

Contributors

Author: J.M. Morgan

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×